|Have Questions?||Leave a Message or Start an on-line Chat|
A synthetic peptide derived from human SNCA was used as the immunogen to immunize an animal to obtain B lymphocytes, which were fused with myeloma cells to generate hybridomas. The sequencing of variable light and variable heavy domains of SNCA antibody-producing hybridomas was performed for vector construction in a recombinant generation. The SNCA monoclonal antibody gene-containing vector was subsequently transfected into cells and cultivated, followed by the isolation and purification of the SNCA recombinant monoclonal antibody using affinity chromatography from the cell culture supernatant. The specificity of the purified antibody was then tested using ELISA and IHC applications. This antibody only detects human SNCA protein.
The SNCA protein is mainly found in the brain and is involved in the regulation of neurotransmitter release and synaptic plasticity. It is also involved in the formation of Lewy bodies, which are pathological hallmarks of Parkinson's disease. SNCA can bind to phospholipids and synaptic vesicles and promote the formation of oligomers and fibrils that can be toxic to neurons. It has also been implicated in other neurodegenerative diseases such as dementia with Lewy bodies and multiple system atrophy.
There are currently no reviews for this product.